Cancer Information

The vast majority of cancers are treatable, with high survival rates and positive prognosis.  A diagnosis with pancreatic, gastro-intestinal, or a rare cancer, however, has the added trauma of limited treatment options, poor survival rates and grim prognoses.

 

Common cancers such as melanoma, breast cancer, prostate cancer and bowel cancer, have seen major progress in treatment options for patients and improved survival over the past 40 years. Survival and treatment options for pancreatic, rare and less common cancers, which encompass the majority of gastro-intestinal cancers, have not seen comparative improvements due to a lack of funding and awareness.

 

Despite collectively representing a leading cause of cancer deaths in Australia, and more broadly the world, gastro-intestinal and rare cancers receive very little government funding in comparison to more common cancers. 

 

WARPNINE seeks to address the inequity in outcomes for these cancers by securing philanthropic funding to support translational research from laboratory to bedside, revolutionary patient focussed projects and clinical trials that have rapid patient benefit.